Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Yu on the Importance of a Genetic Counselor in Prostate Cancer

April 14th 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

Treatment Developments Shaking Up Landscape for Nonmetastatic CRPC

April 13th 2018

Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.

Ongoing Trial to Determine Role of Degarelix in Lowering Cardiovascular AEs in Prostate Cancer

April 12th 2018

The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.

Dr. Hussain Discusses PARP Inhibitors in Prostate Cancer

April 10th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses PARP inhibitors in the treatment of patients with prostate cancer.

Dr. Kelly on the Importance of Local Control in Locally Advanced Prostate Cancer

April 10th 2018

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, director, Division of the Solid Tumor Oncology, Sidney Kimmel Cancer Center, discusses the evolution of local control in locally advanced prostate cancer.

Dr. Den Discusses Bone Metastases in Prostate Cancer

April 4th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone metastases in prostate cancer.

Dr. Yu on Emerging Standards in Radiation for Prostate Cancer

April 2nd 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses emerging standards in radiation for the treatment of patients with prostate cancer.

Multimodal Approaches Emerging in Locally Advanced Prostate Cancer

April 1st 2018

Edouard J. Trabulsi, MD, discusses emerging multimodal treatment approaches for patients with locally advanced prostate cancer.

Prostate Cancer Screening and Surveillance Continue to Evolve

March 30th 2018

William K. Kelly, DO, discusses the evolving imaging techniques and emerging therapeutic approaches in prostate cancer.

Expert Discusses Bone-Targeting Agents in Prostate Cancer

March 29th 2018

Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.

Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate Cancer

March 28th 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.

Genetic Testing Helps Guide Treatment in Prostate Cancer

March 28th 2018

Veda Giri, MD, discusses the developing role of genetic testing for the screening and management of patients with prostate cancer.

Gomella Gives Predictions for Prostate Cancer Advances in 2018

March 25th 2018

Leonard G. Gomella, MD, shares his insight on this year's expected advances in the field of prostate cancer.

Dr. Hussain on the Importance of Next-Generation Sequencing in Prostate Cancer

March 24th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Progessor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cncer Center, Northwestern University Feinberg School of Medicine, discusses the importance of next-generation sequencing in prostate cancer.

Dr. Mann on Differences Between Treatments for Prostate Cancer

March 23rd 2018

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

Frontline Advances Continue in Castration-Sensitive Prostate Cancer

March 23rd 2018

James Luke Godwin, MD, recaps recent advancements in frontline metastatic castration-sensitive prostate cancer and highlights emerging agents with potential in this space.

Dr. Giri Discusses Testing for Inherited Prostate Cancer

March 23rd 2018

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses testing for inherited prostate cancer.

Dr. Gomella on Screening in Prostate Cancer

March 22nd 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, encourages early screening for prostate cancer.

Dr. Den Discusses Bone-Targeting Agents in Prostate Cancer

March 20th 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone-targeting agents in prostate cancer.

FDA Grants Enzalutamide Priority Review for Nonmetastatic CRPC

March 20th 2018

The FDA has granted a priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.